Integrative genomic analysis reveals a conserved role for prolactin signalling in the regulation of adrenal function
Open accessAbstract
We report here that the pituitary hormone prolactin (PRL) has an important, conserved role in regulating adrenal gland function. The adrenal plays a pivotal role in endocrine homeostasis and stress response, which vary across lifespan and have different features in the two sexes.[1] Furthermore, most adrenal disorders have a higher prevalence in women.[2] To get deeper insight into the mechanisms of age- and sex-dependent adrenal function, we performed an integrative analysis of the mouse adrenal transcriptome by RNA-seq and active enhancer (as defined by H3K27ac ChIP-seq) usage at different ages (from E18.5 to P12 weeks) in both sexes. Multivariate analysis showed that age, but not sex, had a significant effect on adrenal global gene expression profiles (Figure and Supporting information S1; Tables S1, S2). Expression of genes related to lipid metabolism and immunity was progressively enriched with age (Figure 1C and Supporting information Table S3), with the proportion of macrophages increasing and neutrophils/mast cells decreasing at older ages (Figure 1D). The expression of different classes of secreted proteins, ion channels and enzymes showed a lower level of sex-dependent enrichment (Figure 1E and Supporting information Table S4). Age-and sex-dependent long non-coding RNA differentially expressed genes (DEG) followed the same pattern as coding DEG, being mostly specific for each age and sex (Supporting information Figure S2 and Table S5). Remarkably, P12 weeks adrenals of both sexes showed increased percentages of novel gene transcripts compared to previous ages (Supporting information Figure S2E). Sexually dimorphic expression pervades all cell populations of the mouse adrenal gland (Supporting information Figure S3 and Table S6). We identified a few thousand enhancers active in the adrenal gland at each temporal stage and in each sex (Supporting information Table S7). A subset among those belong to the super-enhancer class (SEC), genomic regions highly enriched in active chromatin, which regulate developmental and tissue-specific programs and often encompass disease-associated genomic loci.[3] At all ages and in both sexes, adrenal SEC have a much higher level of overlap than typical-enhancer class (TEC) elements (Figure 2A), while adrenal TEC are significantly more conserved than SEC (Figure 2B). Adrenal SEC-associated genes are enriched in genes involved in transcriptional regulation, cell-cell adhesion, protein phosphorylation, biological rhythms and steroid hormone receptor function at all ages and in both sexes (Figure 2C and Supporting information Table S8). Mouse adrenal SEC-associated genes are expressed at significantly higher levels in the adrenal gland (Supporting information Figure S4A) and include a higher percentage of tissue-specific genes (Supporting information Figure S4B) than TEC-associated genes. Human adrenal SEC are also preferentially associated to genes encoding proteins with adrenal-enriched expression than to genes with higher expression in other tissues (Supporting information Figure S4C) and SEC-associated genes are enriched with age-dependent DEG at most times and sex-dependent DEG at P12 weeks compared to TEC (Supporting information Figure S4D,E). Examples of SEC associated to genes important in adrenal physiology are shown in Supporting information Figure S5. Of note, some adrenal SEC-associated genes are expressed preferentially in the adrenal and are involved in blood pressure regulation (Supporting information Table S9). In particular, non-coding SNPs associated with blood pressure traits with very high significance are located inside a conserved SEC encompassing the KCNK3 gene (Supporting information Figure S6 and Table S10). By comparing our list of adrenal sexually dimorphic DEG with data in mouse[4, 5] and rat,[6] we could highlight a core conserved sexually dimorphic gene expression program (Figure 3A and Supporting information Table S11). We focused on the role of the PRL receptor (PRLR), because of its conserved sexually dimorphic expression in the human adrenal (Figure 3B) and the well-known role of PRL signalling in physiological adaptations and response to stress.[7] All Prlr isoforms were upregulated in the female adrenal compared to male at P12, but not P2 weeks of age (Figure 3C). Adrenal gland weight was significantly reduced in adult female Prlr -/- mice compared to WT (Figure 3D), while total body weight was normal in all Prlr -/- animals (Supporting information Figure S7). Signalling pathway impact analysis revealed that the JAK-STAT pathway is significantly activated in female adrenals compared to male at P12 weeks of age (Supporting information Figure S8). The mean area of adrenocortical cells in female Prlr -/- adrenals was significantly decreased (Figure 3E,F). This is consistent with significantly reduced circulating corticosterone levels and a trend toward an increased ACTH/corticosterone ratio in female Prlr -/- mice compared to WT (Figure 3
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
DHEAS levels significantly decrease after dopamine agonist therapy in patients with PRL-secreting pituitary adenomas.
“We recently showed that, among all adrenal steroids, DHEAS levels are selectively increased in patients with PRL-secreting pituitary adenomas (PRLA) compared with patients with hormonally inactive pituitary adenomas and that they significantly decrease after dopamine agonists therapy, suggesting a direct effect of PRL in the regulation of DHEAS production 15 .”
From ACTH and prolactin synergistically and selectively regulate CYP17 expression and adrenal androgen production in human foetal adrenal organ cultures (2023) · cites this paper as [15]
DHEAS levels are selectively increased in patients with PRL-secreting pituitary adenomas compared with patients with hormonally inactive pituitary adenomas.
“We recently showed that, among all adrenal steroids, DHEAS levels are selectively increased in patients with PRL-secreting pituitary adenomas (PRLA) compared with patients with hormonally inactive pituitary adenomas and that they significantly decrease after dopamine agonists therapy, suggesting a direct effect of PRL in the regulation of DHEAS production 15 .”
From ACTH and prolactin synergistically and selectively regulate CYP17 expression and adrenal androgen production in human foetal adrenal organ cultures (2023) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Super-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662 · see citing works
Bôle-Feysot, C., Goffin, V., Edery, M., Binart, N., & Kelly, P. (1998) · Endocrine reviews · doi:10.1210/edrv.19.3.0334 · Cited by 1,973 · see citing works
Adrenal Aging and Its Implications on Stress Responsiveness in Humans
Yiallouris, A., Tsioutis, C., Agapidaki, E., Zafeiri, M., Agouridis, A. P., Ntourakis, D., & Johnson, E. O. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00054 · Cited by 190 · see citing works
Stress-Induced Hyperprolactinemia: Pathophysiology and Clinical Approach
Levine, S., & Muneyyirci‐Delale, O. (2018) · Obstetrics and Gynecology International · doi:10.1155/2018/9253083 · Cited by 118 · see citing works
Glasow, A., Breidert, M., Haidan, A., Anderegg, U., Kelly, P. A., & Bornstein, S. R. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.8.8768882 · Cited by 105 · see citing works
Glasow, A. B. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.8.3103 · Cited by 45 · see citing works
Trejter, M., Hochól, A., Tyczewska, M., Ziółkowska, A., Jopek, K., Szyszka, M., Malendowicz, L. K., & Ruciński, M. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2064 · Cited by 40 · see citing works
Genomic Analysis of Sexual Dimorphism of Gene Expression in the Mouse Adrenal Gland
Wakil, A. E., Mari, B. P., Barhanin, J., & Lalli, E. (2013) · Hormone and Metabolic Research · doi:10.1055/s-0033-1349881 · Cited by 37 · see citing works
Self-citationLyu, Q., Wang, H., Kang, Y., Wu, X., Zheng, H. S., Laprocina, K., Junghans, K., Ding, X., & Huang, C. J. (2020) · Endocrinology · doi:10.1210/endocr/bqaa126 · Cited by 20 · see citing works
Adrenal gland disorders, active component, U.S. Armed Forces, 2002-2017.
Williams, V. F., Oh, G., & Stahlman, S. L. (2018) · PubMed · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Lalli, E., & Figueiredo, B. C. (2022) · BioEssays · doi:10.1002/bies.202200109 · Cited by 10 · see citing works
Self-citationSchneider, G., Ruggiero, C., Renault, L., Doghman-Bouguerra, M., Durand, N., Hingrai, G., Dijoud, F., Plotton, I., & Lalli, E. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad118 · Cited by 3 · see citing works
Self-citation
- Authors
- Ruggiero, C., Altieri, B., Arnold, E., Siqueiros‐Marquez, L., Doghman‐Bouguerra, M., Detomas, M., Durand, N., Jarjat, M., Kurlbaum, M., Chatonnet, F., Deutschbein, T., Clapp, C., & Lalli, E.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- University of Würzburg (DE)
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación (MX)
- Instituto de Neurobiología Universidad Nacional Autónoma de México (UNAM) Queretaro Mexico
- Institut de Pharmacologie Moléculaire et Cellulaire CNRS UMR 7275 Valbonne France
- Inserm (FR)
- Universidad Nacional Autónoma de México (MX)
- Corresponding author
- Lalli, Enzo
- ORCID
- Venue
- Clinical and Translational Medicine
- Publisher
- Wiley
- Published
- 2021-11
- Volume
- 11
- Issue
- 11
- Pages
- e630-e630
- ISSN
- 2001-1326 (ISSN-L)
- PMC
- PMC8574957
- OpenAlex
- W3212538573
- Cited by
- 10
- References
- 10
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 2 · 2023: 2 · 2022: 1
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical and Translational Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Agence Nationale de la Recherche (ANR-15-CE14-0017, ANR-20-CE14-0007)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Keywords
- adrenal function, adrenal gland, integrative genomics
- MeSH terms
- Whole Genome Sequencing, Adrenal Glands, Humans, Prolactin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review